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Background: Endovenous laser therapy (EVLT) for ablation of the great saphenous vein (GSV) is thought to minimize
postoperative morbidity compared with high ligation and stripping (HL/S). Only a few randomized trials have reported
early results. This prospective randomized trial compared EVLT (980 nm) and HL/S results at 1 and 2 years after the
intervention.
Method: Patients with symptomatic varicose veins due to GSV insufficiency were randomized to HL/S (100 limbs) or
EVLT (104 limbs). Four EVLT procedures failed primarily and were excluded. Phlebectomy and ligature of
incompetent perforators were performed whenever indicated in both groups. Patients were re-examined clinically
and by duplex ultrasound imaging preoperatively and at 12 days and at 1 and 2 years after treatment. Closure rate,
complication rate, time to return to normal activity, the Aberdeen Varicose Vein Symptom Severity Score (AVVSS),
the Varicose Venous Clinical Severity Score (VVCSS), and the Medical Outcome Study Short Form-36 scores were
also recorded.
Results: There were no differences in patient demographics, CEAP class, Widmer class, or severity scores between the
groups. Simultaneous interventions did not differ between the groups. Similar times for the return to normal activity
and scores for postoperative pain were reported. No major complications after treatment were recorded. HL/S limbs
had significantly more postoperative hematomas than EVLT limbs, and EVLT patients reported more bruising.
Follow-up at 1 year was 100% for HL/S and 99% for EVLT. Two GSVs in the EVLT group reopened and three
partially reopened. No open GSVs occurred in HL/S limbs. Ninety-eight percent of the limbs in both groups were
free of symptoms. VCSS, AVVSS, and Short Form-36 scores did not reveal any group differences. At 2 years, no
differences compared with 1-year results were observed, except that two more GSVs in the EVLT group were
partially reopened.
Conclusions: Abolition of GSV reflux and improvement in quality of life was similar after HL/S and EVLT. After EVLT,
however, twoGSVs were found completely reopened and five were partially reopened, which was significantly higher than
after HL/S. A prolonged follow-up is ongoing. (J Vasc Surg 2010;52:1234-41.)Varicose veins caused by great saphenous vein (GSV)
insufficiency and reflux are common, and until recently,
high ligation and stripping (HL/S) of the GSV has been
the standard treatment.1 HL/S has been reported to
improve disease-specific and general quality of life of the
patients,2,3 with a low incidence of postoperative com-
plications. Less invasive techniques have been developed
in recent years, including radiofrequency ablation, en-
dovenous laser (EVLT) ablation, foam sclerotherapy,
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1234and cryostripping, and are reported to achieve control of
insufficient truncal vein.
The most commonly used procedure so far has been
EVLT. EVLT is thought to minimize morbidity after
treatment compared with HL/S, including avoidance of
a groin incision and dissection at the saphenofemoral
confluence, which has been reported to result in a lower
complication rate and reduce posttreatment discomfort
and pain, with a faster resumption of normal activity.4-7
Early recanalization has been reported to occur in 5% to
9% after EVLT,8 and long-term results from randomized
controlled trials (RCTs) are still lacking. However, a
recent systemic review found very few studies have actu-
ally compared HL/S with EVLT,9 and of those, only
three randomized controlled studies have thus far re-
ported early results.10-12
This prospective randomized trial compares EVLT
with the standard HL/S surgical procedure of the GSV to
identify differences between these ablation techniques in
efficacy concerning permanent GSV closure and absence of
detectable venous reflux up to 2 years after the procedure,
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patient satisfaction.
PATIENTS AND METHODS
The study was approved by the hospital’s ethical com-
mittee (05-014 [NAC 05-004]), and all participating pa-
tients signed an informed consent form.
The study design. This was a prospective randomized
clinical trial with two treatment arms of 100 limbs each.
Group 1 received conventional HL/S surgery for GSV
insufficiency, and group 2 received EVLT ablation using a
980-nm diode laser (Endovenous Laser OptoLight 25
W/980 nm Endosysteme, Villeurbanne, France).
Inclusion criteria. Patients in good general health
presenting with progressive superficial venous insufficiency
(Widmer class 0 to III) and/or C2-6, S, Ep, As2-3As1 and
Ap17-18, Pr, according to the CEAP classification,
13 were
eligible for enrollment if pretreatment duplex ultrasound
(DUS) scanning demonstrated reflux at the saphenofemo-
ral confluence during Valsalva maneuver together with a
GSV diameter of 5 to 15 mm at 3 cm from the saphe-
nofemoral junction with the patient prone and truncal
reflux 0.5 seconds, where an active intervention was
indicated.
Exclusion criteria. Venous reoperations, pregnant or
breast-feeding women, patients aged 18 years; a history
of deep vein thrombosis or pulmonary embolism, or both,
or postthrombotic changes observed at DUS examination;
patients with cancer, coagulopathy, and ongoing anticoag-
ulation therapy; patients with pacemakers; and patients
with symptomatic arterial disease or no peripheral arterial
pulse on clinical examination.
Once a patient was eligible to participate in the trial,
randomizationwas performed using a computerized random-
ization tool. The study design adhered to the Consolidated
Standards of Reporting Trials (CONSORT)model14 (Fig 1).
Enrollment for the study started in March 2006.
All EVLT or HL/S procedures, including additional
phlebectomies and ligature of incompetent perforators,
were done by the same surgeon (J. T. C.). All preoperative
and postoperative clinical evaluations, postoperative inter-
views, and clinical examinations were done by the same
surgeon (J. T. C.). An independent angiologist (S. G.)
performed the preoperative and postoperative DUS scan-
ning with the patient standing, following a standardized
protocol that evaluated abolition of the GSV or presence of
reflux, or both. Flow was defined as being antegrade.
Reflux was defined as retrograde flow of 0.5 second after
Valsalva maneuver or manual compression and decompres-
sion of the distal vein. Even a slight reflux in the proximal
segment of an occluded GSV was assessed as pathologic.
The DUS examination was performed preoperatively, im-
mediately after the intervention and at 4 to 6 hours, at 12
days, and at 1 and 2 years.
The Medical Outcome Study Short Form 36 (SF-36)
health-related quality-of-life score,15 the Aberdeen Vari-
cose Vein was Symptom Severity Score (AVVSS), and the
Varicose Venous Clinical Severity Score (VVCSS)16 wererecorded for each patient preoperatively and postopera-
tively during the follow-up.
High ligation and stripping. Ligation of the saphe-
nofemoral junction together with ligation of all tributary
veins was performed through a 1- to 2-cm groin incision. A
standard stripper was inserted in the GSV, and the vein was
stripped top down either to just below the knee or at the
ankle (4-mm skin incision). Stab evulsions using small skin
incisions of marked varicose branches and ligation of
grossly incompetent perforators was performed whenever
needed. The groin and distal incisions were closed by an
intradermic continuous suture with 3-0 Monocryl (Ethi-
con, Johnson & Johnson, Neuchâtel, Switzerland).
EVLT. The EVLT ablation was performed using a
980-nm diode laser under DUS guidance. In the initial 49
patients, the optic fiber was introduced using a sheath and
guidewire, and in 51 patients, a direct puncture of the GSV
was used to introduce the optic fiber (denuded, 600-m,
0.038-inch; Endosysteme, Villeurbanne, France). Four pa-
Fig 1. This randomized prospective trial compared endovenous
laser and surgical ablation of primary great saphenous vein incom-
petency. This Consolidated Standards of Reporting Trials (CON-
SORT)14 diagram shows trial recruitment, randomization, and
treatment allocation for limbs evaluated and studied as well as
follow-up (FU) analysis.tients required a small surgical cutdown. EVLT was not
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spasm. These patients were excluded from the trial.
The desired position of the laser optic fiber tip (1 to 2
cm distal to the saphenofemoral junction) was confirmed
with DUS scanning. Tumescent anesthesia17 was adminis-
tered in all patients with a syringe under US guidance to
ensure a homogenous layer of tumescent fluid around the
GSV, using approximately 250mL per treatment. The laser
energy (10 to 12 W) was delivered during a stepwise
retraction of the optic fiber (1.5-second impulse and 1.5-
second pause). Laser treatment data are given in Table I.
Stab evulsions of marked varicose branches and ligation
of grossly incompetent perforators was performed when-
ever needed and were equally distributed between the two
treatment groups.
All HL/S and EVLT procedures were performed with
general or spinal anesthesia, in 90% as an ambulatory pro-
cedure, without group difference. After the procedure, the
leg was wrapped in sterile absorbent bandages and covered
with a double-layered elastic bandage that was changed
before discharge (4 to 6 hours after the treatment). After 48
hours, the patient removed the bandage and continued
using a class II (30 mm Hg) below-knee elastic stocking
(Sigvaris; Ganzone &Cie AG, St Gallen, Switzerland) for 3
weeks during the day only. Depending on weight, the
patient received thrombosis prophylaxis using enoxaparin
(20 or 40 mg; Clexane, Sanofi-Aventis, Meyrin, Switzer-
land) subcutaneously 6 hours after the treatment once daily
for 10 days.
Patient characteristics. Patient demographics are
presented in Table II. There were no group differences
regarding sex, age, body mass index, or size of the GSV 3
cm below the saphenofemoral junction.
Technical results and complications were recorded, and
the patients completed the scoring forms. Technical success
Table I. Outcomes in 100 limbs undergoing great
saphenous vein (GSV) ablation by endovenous laser
therapy (EVLT) for primary varicose veins
Variables No. or mean  SD (range)
Difficult access for percutaneous
fiber insertiona 8
Surgical cutdown 4
Sheath and guidewire use for
optic fiber insertion 49
Direct puncture and placement
of optic fiber 51
Distance of GSV treated, cm 35.5  6.3 (18-50)
Energy delivered, J 2724.4  703.0 (1236-4254)
Energy delivered, J/cmb 75.9  12.8 (40.4-108.0)
Distance to saphenofemoral
confluence, cm 1.63  1.6 (0.4-28.2)
aExtremely obese patients and/or rolling veins which prolonged the proce-
dure or surgical cutdown was necessary (n  4).
bEleven limbs were treated with 70 Joules/cm. The GSVs in all of these
limbs were successfully obliterated, and none of these GSVs reopened during
the follow-up.was defined as absent GSV in the HL/S group and closedGSV without any flow in the EVLT group. During the first
12 days postoperatively, the patients were asked to indicate
themaximum area of hematomas or bruising, the exact date
of return to normal activity, to indicate pain using a visual
analog scale from 0 to 10, and to record intake of analge-
sics. The primary end point was closed or absent GSV with
reflux, and secondary end points were return to normal
activity, treatment-related complications, and scores for
VVCSS, AVVSS, and SF-36.
Statistics. Data are presented as mean  standard
deviation. Continuous variables were analyzed with t test
and categoric variables using the 2 test. A value of P .05
was considered statistically significant. Sample size calcula-
tions by a biostatistician before the start of the trial revealed
that a group size of 100 limbs in each group had a statistical
power of 80%, with the confidence interval set at 96%, to
detect a difference in the primary study end point between
EVLT and HL/S of 0.05.
RESULTS
During the enrollment phase, 425 limbs were assessed
for eligibility, 204 limbs were randomized, and 4 limbs
were excluded in the EVLT group, leaving 100 limbs in
each group for analysis. All limbs were examined on post-
operative day 12. At 1 year after treatment, 1 limb was lost
to follow-up in the EVLT group, leaving 99 limbs for
evaluation. At the 2-year follow-up, another 4 limbs in the
EVLT group (3 limbs operated on and 1 limb lost to
follow-up) and 1 limb in the HL/S group were lost to
follow-up, thus allowing 2-year analysis of 95 and 99 limbs,
respectively (Fig 1).
There was no significant difference between the groups
regarding treatment time (31.4 7.8minutes [HL/S] and
32.0  7.4 minutes [EVLT], respectively). In the HL/S
Table II. Patient characteristics in 100 legs undergoing
great saphenous vein (GSV) ablation by surgery (HL/S)
and 100 legs by endovenous laser therapy (EVLT)
Variables HL/S EVLT
Limbs, No. 100 100
Female sex 71 67
Age, y
Mean  SD 46.3  13.3 44.6  10.5
Range 24-86 24-79
BMI, kg/m2
Mean  SD 26.0  5.1 26.2  4.8
Range 16.9-40.5 18.2-42.2
Obesity (BMI 30 kg/m2),
No. 12 17
Size of GSV at 3 cm from
SFJ, mm
Mean  SD 6.6  1.7 6.9  2.0
Range 4.4-12.8 4.2-12.5
Reflux time, s 2.4  1.1 2.5  0.9
Deep venous reflux 4/26 2/24
BMI, Body mass index.
P values were not statistically significant.group, there were no perioperative complications, whereas
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fiber insertion site.
Pretreatment varicose vein symptoms and severity clas-
sifications (CEAP, VVCSS and AVVSS) are reported in
Table III and revealed no group differences. The HL/S
group had a higher incidence of dermatitis compared with
the EVLT group, whereas there were no significant differ-
ences between the groups regarding severity classifications
(Table III).
The postoperative DUS examination 6 hours and at 12
days revealed absence or abolishment of the GSV in all
treated legs in both groups. One limb in the EVLT group
showed reflux at the level of the thigh. Time to return to
normal activity was 6.6 days forHL/S vs 6.9 days for EVLT
(Table IV). Pain scores were without significant group
differences throughout the first 12 postoperative days, with
an average pain score of 4.6 for HL/S and 4.3 for EVLT on
day 1, 2.9 vs 2.2 on day 3, and 1.8 vs 1.7 on day 12. There
was no group difference in the mean use of analgesics
during the initial 12 postoperative days. Few complications
occurred after treatment (Table IV). All patients were
specifically asked about any neurologic symptoms at each
follow-up visit. The area of maximum hematoma or bruis-
ing was marked by the patient in addition to a nonquantifi-
able observation by the examiner. More hematomas occurred
after HL/S than after EVLT, which was counteracted by
significantly more bruising in the EVLT group than in the
Table III. Pretreatment varicose vein symptoms and
classifications in 100 legs undergoing great saphenous
vein (GSV) ablation for primary varicose veins by high
ligation and stripping (HL/S) and 100 legs by
endovenous laser therapy (EVLT)
Variables HL/S EVLT P
Pain, No. 100 100 .1
Heaviness, No. 90 89 .823
Edema, No. 72 61 .099
Dermatitis, No. 24 8 .002
Skin changes
With open venous ulcer 3 0 .123
With healed venous ulcer 2 1 .1
ABI, mean  SD 0.9  0.1 0.9  0.1 .1
Primary varicose veins of
GSV, No.
100 100 1.0
CEAP, No.
C2 26 34 .218
C3 51 58 .393
C4 18 7 .031
C5 2 1 1.0
C6 3 0 .123
C4-C6 23 8 .041
VVCSS .1
Mean  SD 5.2  2.7 5.2  2.5
Range 2-18 2-16
AVVSS .1
Mean  SD 22.0  7.5 22.5  6.5
Range 10-46 12-42
ABI, Ankle-brachial index; AVVSS, Aberdeen Varicose Vein Severity Score;
VVCSS, Varicose Vein Clinical Severity Score.HL/S group.No limbs were lost to follow-up during the first year,
but one limb was lost during the second year in the HL/S
group. In the EVLT group, one limb was lost to follow-up
during the first year because the patient withdrew from the
study. Another four limbs in the EVLT group were not
available for analysis during the second year of follow-up
because three underwent surgery due to a reopened GSV,
thus leaving us with completed follow-up of 99% in the
HL/S group and 95% in the EVLT group.
Outcomes at 1 and 2 years after ablation of the GSV by
HL/S or EVLT are presented in Table V. The mean
VVCSS and AVVSS in the HL/S group were significantly
decreased, from 5.2 2.7 and 22.0 7.5 preoperatively to
0.23  0.57 and 4.17  1.97, respectively, 1 year after
treatment. At 2 years, no further significant improvement
was noted. Similar development was noted for the EVLT
group (Tables III and V).
In theHL/Sgroup, therewas a 100% absence of theGSV
at 1 and 2 years postoperatively. At the 1-year follow-up in the
EVLT group, two GSVs had reopened (with symptoms, re-
operated on, and lost to further follow-up) and three GSVs
had partially reopened (withmild symptoms). At 2 years, an
additional 2 GSVs had partially reopened, one with symp-
toms, and underwent subsequent surgical ablation. How-
ever, the difference in treatment failure at 2 years between
EVLT (7 of 98) and HL/S (0 of 99) did not reach statistical
significance (P .051, Table V).
In four limbs, intention to treat by EVLT was aban-
doned because severe spasm prevented introduction of the
optic fiber. These patients were excluded. If, however,
failure of intention to treat is addressed, there was a highly
significant difference between the treatment groups in favor
of HL/S (0 of 99) compared with EVLT (11 of 102; P 
.016).
Quality-of-life measurement, using SF-36, showed im-
Table IV. Technical results and complications after great
saphenous vein (GSV) ablation by high ligation and
stripping (HL/S) and endovenous laser therapy (EVLT)
at 12 days postoperatively
Variables HL/S EVLT P
Limbs, No. 100 100
GSV absent or abolished,
No. 100 100 1.0
Detectable reflux, No. 0 1 .1
Symptoms, No. 18 23 .380
Time to return to normal
activity, d .5
Mean  SD 6.6  2.1 6.9  2.7
Range 2-14 3-21
Complications, No.
Infection 0 0 1.0
Superficial localized
phlebitis 1 4 .369
Deep vein thrombosis 0 0 1.0
Hematoma 12 5 .076
Transient paresthesia 1 1 1.0
Bruising 2 15 .002provement in most parameters comparing preoperative and
; SF, sa
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(BP), vitality (VT), and physical functioning (PF) were the
dimensions most markedly improved at 1 year in both
groups (Fig 2). There were no differences between results
at 1 and 2 years in either group.
A comparison of HL/S and EVLT ablation of the GSV
for primary incompetency 2 years later revealed a signifi-
cantly higher incidence of completely reopened and par-
tially reopened GSVs after EVLT than after HL/S (7 vs 0,
P .051), more limbs with symptoms (9 vs 1), and a longer
distance to the saphenofemoral junction (9.3 vs 5.5 mm,
P  .001). However, there were no significant group
differences in quality-of-life or venous severity scoring at 2
years after GSV ablation (Table VI).
DISCUSSION
Initial and short-term good results have been published
in the literature with the use of various endovenous treat-
ment modalities of varicose veins, but few RCTs have been
reported so far. High-quality large comparative RCTs on
long-term clinical efficacy (recurrent varicose veins), safety,
and quality-of-life outcomes would be required before
considering endovenous techniques as a validated alterna-
tive treatment, even though some authors have stated
EVLT as the standard of care on the basis of long-term
Table V. Outcomes in 100 legs undergoing great sapheno
100 legs by endovenous laser therapy for primary GSV insu
Variables
High ligation and stripping
Total limbs, No.
Lost to follow-up, No.
Available for follow-up, No.
Analyzed, No.
GSV absent, No.
Reflux, No.
Limbs with symptoms, No.
Retouch miniphlebectomy, No.
GSV reoperation, No.
VVCSS, mean  SD (range)
AVVSS, mean  SD (range)
Distance to SF confluence, mean  SD (range), mm
Endovenous laser therapy
Total, No.
Lost to follow-up, No.
Available for follow-up, No.
Analyzed, No.
GSV completely occluded, No.
GSV open, No.
GSV partially open, No.
Reflux, No.
Limbs with symptoms, No.
Retouch miniphlebectomy, No.
GSV reoperation, No.
VVCSS, mean  SD (range)
AVVSS, mean  SD (range)
Distance to SF confluence, mean  SD (range), mm
ABI, Ankle-brachial index; AVVSS, Aberdeen Varicose Vein Severity Scoreobservational single-center studies.17,18One RCT has reported no difference in pain score,
but less bruising and edema after EVLT compared with
HL/S.19 Another recent RCT showed a similar short-
term efficacy and safety of EVLT and HL/S.10 Compa-
rable efficacy and disease-specific quality of life has been
reported after EVLT and HL/S, but earlier return to normal
activity is reported after EVLT.12 We report here the largest
study comparing EVLT and HL/S with a 2-year complete
follow-up.
We first confirmed from available data that HL/S and
EVLT for GSV reflux are initially similarly effective for
treating GSV reflux.10,12 Also corresponding with earlier
reports10,12 were improvement of quality of life and signif-
icant improvement in clinical severity scores (VVCSS and
AVVSS) and in CEAP classification, which was docu-
mented during follow-up for both treatment groups. In
contrast to previous reports, however, the two groups had
similar postoperative pain scores and time for return to
normal activity because the HL/S group experienced more
postoperative hematomas, and the EVLT patients had sig-
nificantly more bruising. Perhaps these results will change
with the use of new types of optical fibers20 and lasers with
different wavelengths,21 but long-term results from RCTs
are still lacking for such refinements of EVLT.
We, importantly, did not observe any major complica-
ein (GSV) ablation by high ligation and stripping and
ency
Follow-up period
12 days to 1 year 1 to 2 years
100 100
0 1
100 99
100 99
100 99
1 1
1 0
3 4
0 0
0.23  0.57 (0-3) 0.23  0.59 (0-3)
4.17  1.97 (2-14) 3.54  2.30 (2-20)
6.21  3.34 (0-21) 5.46  3.25 (0-20)
100 99
1 4
99 95
99 95
94 88
2 0
3 2
4 4
5 4
8 6
2 1
0.26  0.68 (0-3) 0.23  0.54 (0-2)
4.53  3.10 (3-22) 3.82  1.35 (1-10)
9.54  7.49 (0-50) 9.28  6.89 (0-45)
phenofemoral; VVCSS, Varicose Vein Clinical Severity Score.us v
fficitions, such as deep vein thrombosis or wound infection, in
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each group experienced transient paresthesia, and superfi-
cial localized thrombophlebitis in a nontruncal side branch
Fig 2. Medical Outcomes Study Short Form-3615 results preoper-
atively and at 1 year after ablation of great saphenous vein by (A) high
ligation and stripping (HL/S) or (B) endovenous laser (EVLT) in
limbs presenting with primary GSV reflux. Dimensions measured
were physical functioning (PF), role-physical (RF), bodily pain (BP),
general health (GH), vitality (VT), social functioning (SF), role-
emotional (RE), and mental health (MH). Mean data are presented.was observed in one limb in the surgery group and in fourlimbs after laser ablation. All treatments were performed by
a highly specialized and experienced surgeon, which may
have contributed to the low incidence of complications.
One surgical failure occurred in the HL/S group, where a
thigh reflux was observed at the 1-year control, probably due
to amissed duplication of the GSV. This contrasts with earlier
reports, well keeping in mind that the postoperative period of
2 years is most likely too short for neorevascularization at the
saphenofemoral confluence.12,22
In our series, the initial closure rate immediately post-
operatively and at 12 days was 100%, without detectable
reflux in both groups. High success rates after EVLT have
been reported. A 2-year recurrence rate of 10% was
reported by Min et al23 in 2003. Proebstle et al24 showed
that the energy delivery had an important effect on recur-
rence, where low-energy delivery had worse results and
more recurrences than higher-energy doses.24 Yet in a
recent study, Pannier and Rabe25 demonstrated that large
vein diameter, when moderate energy delivery was used
(48.6 J/cm) was associated with nonocclusion of the
treated vein. The mean laser energy delivery in the present
series was 75.9  12.8 J/cm, which has been reported to
achieve permanent GSV ablation.24,26
At 1-year follow-up, GSV abolishment, without detect-
able DUS GSV reflux, was observed in 99% in the surgery
group. Contrary to the HL/S group, recanalization with a
completely reopened GSV with GSV reflux was diagnosed
in two limbs in the EVLT group. DUS scanning in both
limbs showed a completely obstructed GSV immediately
postoperatively and at the 12-day follow-up. Because these
Table VI. Outcomes comparison between high ligation
and stripping (HL/S) and endovenous laser therapy
(EVLT) for abolition of primary great saphenous varicose
veins at the 2-year follow-up
Variables HL/S EVLT P
Limbs lost to follow-up,
No. 1 5 .212
Limbs analyzed, No. 99 95 .212
Primary end point
Great saphenous vein, No.
Absent/completely
closed 99 88 1.0
Completely reopened 2
Partially reopened 5
Completely  partially
reopened or
detectable 0 7 .051
Reflux, No. 2 8 .050
Limbs with symptoms,
No. 1 9 .007
Limbs reoperated on, No. 0 3 .102
VVCSS, mean  SD 0.23  0.59 0.23  0.54 .1
AVVSS, mean  SD 3.54  2.30 3.82  1.35 .050
Distance to SF confluence,
mean  SD, mm 5.46  0.25 9.28  6.89 .001
AVVSS, Aberdeen Varicose Vein Severity Score; SF, saphenofemoral;
VVCSS, Varicose Vein Clinical Severity Score.two patients presented with recurrent symptoms, both
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up. A partially reopened GSV with reflux from the saphe-
nofemoral junction to midthigh was found in another three
limbs. These patients were asymptomatic at the 1-year
control, in keeping with earlier reports.10,12,23,24
At 2 years, an additional limb in the surgery group
revealed mild, short reflux at the saphenofemoral junction,
with no visible recurrence of varicose veins and no symp-
toms. Yet another two limbs in the EVLT-group showed
long reflux in partially opened GSVs. These patients were
asymptomatic, however, and required no further treat-
ment. One patient with a partially reopened GSV to the
distal part of the thigh at 1 year became severely symptom-
atic with recurrent varicosities and underwent HL/S at 1
year and 7 months after the initial treatment.
None of the patients with complete or partial recanali-
zation of their GSV after EVLT had received a laser energy
delivery 67 J/cm at the initial treatment. Even though
early recanalization of EVLT could mimic recanalization
seen after thrombophlebitic occlusion, as described by
Proebstle et al,27 the later recanalization that was seen in
our series is more difficult to explain. The distance to the
saphenofemoral junction may play a role, because the dis-
tance was significantly shorter in the HL/S group than in
the EVLT group. The distance from the saphenofemoral
confluence to the ligature and the obliteration, respectively,
diminished slightly but remained significantly different.
This may have an important effect on the rate of neorevas-
cularization later on, even though some evidence has been
presented in the literature suggesting that EVLT, unlike
surgery, is associated with a very low incidence of neo-
revascularization.28,29 However, long-term follow-up
would be required to correctly address this issue.
The recanalization rate of symptomatic limbs at 2 years
was 3.2% (3 of 95), which corresponds to the 3% recanali-
zation rate after EVLT reported in a large series of 1250
patients28 and the 3.7% reported by Darwood et al12 in
2008. However, if one also considers partially reopened,
nonsymptomatic GSVs, the recanalization rate increases to
7.4%, which is in the range of the 10% reported by Min et
al23 and close to being significantly higher than after ade-
quate surgery performed by expert surgeon (P  .051).
CONCLUSION
Abolition of GSV reflux, safety, improvement in quality
of life, and clinical severity score were similar after HL/S
and EVLT. At 2 years after treatment, however, two GSVs
were completely reopened and five were partially reopened
after EVLT, which was significantly higher than after
HL/S. Three of these patients required a reintervention
due to recurrent symptoms. Follow-up is continuing to
evaluate the rate of neorevascularization after the two treat-
ments.
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